The effect of vitamin D supplementation on the gut microbiome in older Australians - Results from analyses of the D-Health Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers analyzed data from the D-Health Trial, a randomized, double-blind, placebo-controlled trial.

Stool samples were collected from a sample of 835 participants (417 in the placebo and 418 in the vitamin D group) approximately 5 y after randomization.

Who Took Part

The study group was 835 participants.

The age groups tagged for this paper are older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The subject headings attached to it are RNA, Ribosomal, 16S, Gastrointestinal Microbiome, Bacteroidetes, Dietary Supplements, Australia, Bacillota and Vitamin D.

Author keywords: Gut microbiome, randomized controlled trial and vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 835 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2023 (Gut microbes), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.